Figure 3.

Impact of plasma NGS at time of biopsy on time-to-treatment. (A) Comparison of the total number of driver mutations detected in both cohorts. (B) Comparison of NGS results available at the first oncology visit between cohorts. Tissue results available depicted in gray and plasma NGS results depicted in blue. (C) Percentage of patients receiving a specific treatment recommendation at the first oncology visit. (D) Median time-to-time treatment between cohorts. Cohort^D depicts patients with a therapeutically informative driver mutation detected. NGS, next-generation sequencing.